Trial Profile
A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- 11 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 12 Dec 2017 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.
- 12 Dec 2017 Status changed to active, no longer recruiting.